Abrocitinib: A Comprehensive Review of its Efficacy and Safety in Dermatology
Abrocitinib is a novel oral small molecule which acts as a selective JAK-1 inhibitor. Currently approved for use in moderate-to-severe cases of atopic dermatitis, this drug is gaining a rapid impetus for its use across various inflammatory dermatoses for its selective downstream action on cytokines...
Saved in:
Main Authors: | Sunil Dogra (Author), Shikha Shah (Author), Manavi Gupta (Author), Ayush Sharma (Author), Seema Chhabra (Author) |
---|---|
Format: | Book |
Published: |
Wolters Kluwer Medknow Publications,
2024-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Emerging role of baricitinib in dermatology practice: All we need to know!
by: Sunil Dogra, et al.
Published: (2023) -
Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis
by: Helena Iznardo, et al.
Published: (2023) -
Mycobacterium indicus pranii (MIP) vaccine: Pharmacology, indication, dosing schedules, administration, and side effects in clinical practice
by: Sunil Dogra, et al.
Published: (2023) -
Efficacy and safety of abrocitinib for moderate-to-severe atopic dermatitis in adolescents and adults: Meta-analysis
by: Ling Li, et al.
Published: (2023) -
The Efficacy and Safety of Abrocitinib as a Treatment Option for Atopic Dermatitis: A Short Report of the Clinical Data
by: Napolitano M, et al.
Published: (2021)